Novo Nordisk (NYSE: NVO) has lifted its full-year 2026 guidance after reporting second-quarter adjusted sales of DKK 78.5 billion, reflecting 7% growth at constant exchange rates. Millar said weekly prescriptions for the oral Wegovy treatment reached 267,000 as of July 17, with the product capturing approximately 90% of the U.S. oral obesity-medication market despite new competition entering in early April. Around 80% of oral Wegovy users were new to GLP-1 treatments, suggesting the pill is expanding the addressable patient population rather than simply cannibalizing existing injectable therapy users. International obesity sales rose 37%, reinforcing the view that demand for the company’s weight-loss franchise remains robust well beyond the U.S. market. Novo Nordisk also flagged ongoing headwinds including expected U.S. sales declines, greater pricing pressure, reduced Medicaid coverage, and rising generic competition across parts of its broader portfolio.